Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
Date: February 21, 2022
Issue #:
1644Summary:
Odevixibat (Bylvay– Albireo), an oral ileal bile acid
transporter (IBAT) inhibitor, has been approved by the
FDA for treatment of pruritus in patients ≥3 months
old with progressive familial intrahepatic cholestasis
(PFIC). It is the first drug to be approved in the US for
this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Actigall Antihistamines Bylvay Naltrexone odevixibat Rifampin Urso ursodeoxycholic acid Ursodiol Source Type: research